Q-omics provides the consensus-scored SPATA31C1 profile across patient tissues and cancer cell-line models. SPATA31C1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SPATA31C1 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, SPATA31C1 RNA expression shows 11,595 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, COAD, and TGCT as cancer lineages where SPATA31C1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA31C1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA31C1 survival associations across molecular data types. SPATA31C1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA31C1 RNA expression–survival associations across cancer types. High SPATA31C1 expression shows unfavorable associations in LIHC, KICH, DLBC, LUAD and CHOL, but favorable associations in BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SPATA31C1 RNA expression.
This table summarizes SPATA31C1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA31C1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA31C1 shows lower tumor expression in COAD, KICH, KIRC and LUSC and higher tumor expression in BRCA. The COAD box plot shows higher SPATA31C1 RNA expression in normal versus tumor tissue (log2 FC = −0.037, t-test p < 0.001).
This table shows molecular features associated with SPATA31C1 in patient tissues and cancer cell lines. In patient samples, SPATA31C1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
